ticlopidine has been researched along with Hypertrophy in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graciano, ML | 1 |
| Nishiyama, A | 1 |
| Jackson, K | 1 |
| Seth, DM | 1 |
| Ortiz, RM | 1 |
| Prieto-Carrasquero, MC | 1 |
| Kobori, H | 1 |
| Navar, LG | 1 |
1 other study available for ticlopidine and Hypertrophy
| Article | Year |
|---|---|
Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.
Topics: Actins; Adenosine Triphosphate; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Proliferat | 2008 |